Metropolitan Life Insurance Company (MetLife)’s Tempest Therapeutics TPST Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio TPST Stock Details TPST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-9	Closed	-$190K	–	2644
2016 Q3	$190K	Buy	+9	New	+$163K	﹤0.01%	2368
2016 Q1	–	Sell	-6	Closed	-$162K	–	2525
2015 Q4	$162K	Hold	6	–	–	﹤0.01%	2392
2015 Q3	$141K	Hold	6	–	–	﹤0.01%	2509
2015 Q2	$495K	Buy	6 +1	+20%	+$91.6K	﹤0.01%	1749
2015 Q1	$465K	Hold	5	–	–	﹤0.01%	1596
2014 Q4	$592K	Hold	5	–	–	﹤0.01%	1653
2014 Q3	$222K	Buy	+5	New	+$175K	﹤0.01%	2299

Other funds holding TPST

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return

CQS Cayman Camana Bay, Grand Cayman, Cayman Islands $2.26B AUM 1.31% 1-Year Est. Return

PCM

Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s TPST Position: Q4 2016 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Tempest Therapeutics (TPST) in Q4 2016, closing a stake of 9 shares — an estimated $190K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in TPST in Q3 2014 and held it in 7 quarters. The position peaked at $592K in Q4 2014. 84 funds tracked by Wall St. Rank hold TPST as of Q4 2016.

Metropolitan Life Insurance Company (MetLife) reported no remaining Tempest Therapeutics position as of Q4 2016 after selling out during the quarter.
Metropolitan Life Insurance Company (MetLife) sold 9 Tempest Therapeutics shares in Q4 2016, an estimated $190K.
Metropolitan Life Insurance Company (MetLife) first reported a position in Tempest Therapeutics in Q3 2014 and held it in 7 quarters.
Metropolitan Life Insurance Company (MetLife)'s Tempest Therapeutics position peaked at $592K in Q4 2014.
84 funds tracked by Wall St. Rank held Tempest Therapeutics as of Q4 2016.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q4 2016, filed 14 Feb 2017.